200 related articles for article (PubMed ID: 12682274)
21. Nontypeable Haemophilus influenzae Lipooligosaccharide Expresses a Terminal Ketodeoxyoctanoate
Apicella MA; Coffin J; Ketterer M; Post DMB; Day CJ; Jen FE; Jennings MP
mBio; 2018 Jul; 9(4):. PubMed ID: 30065093
[TBL] [Abstract][Full Text] [Related]
22. Sialic Acid Protects Nontypeable Haemophilus influenzae from Natural IgM and Promotes Survival in Murine Respiratory Tract.
Jackson MD; Wong SM; Akerley BJ
Infect Immun; 2021 May; 89(6):. PubMed ID: 33782153
[TBL] [Abstract][Full Text] [Related]
23. Effect of primary immunization on pulmonary clearance of nontypable Haemophilus influenzae.
McGehee JL; Radolf JD; Toews GB; Hansen EJ
Am J Respir Cell Mol Biol; 1989 Sep; 1(3):201-10. PubMed ID: 2624760
[TBL] [Abstract][Full Text] [Related]
24. Intranasal coinfection model allows for assessment of protein vaccines against nontypeable Haemophilus influenzae in mice.
Michel LV; Kaur R; Zavorin M; Pryharski K; Khan MN; LaClair C; O'Neil M; Xu Q; Pichichero ME
J Med Microbiol; 2018 Oct; 67(10):1527-1532. PubMed ID: 30136923
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.
Yu S; Gu XX
Infect Immun; 2005 May; 73(5):2790-6. PubMed ID: 15845482
[TBL] [Abstract][Full Text] [Related]
26. PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice.
Siggins MK; Gill SK; Langford PR; Li Y; Ladhani SN; Tregoning JS
Vaccine; 2015 Sep; 33(38):4954-61. PubMed ID: 26212006
[TBL] [Abstract][Full Text] [Related]
27. Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae.
Khan MN; Ren D; Kaur R; Basha S; Zagursky R; Pichichero ME
Expert Rev Vaccines; 2016 Jul; 15(7):863-78. PubMed ID: 26894630
[TBL] [Abstract][Full Text] [Related]
28. Recombinant truncated E protein as a new vaccine candidate against nontypeable H. influenzae: Its expression and immunogenic evaluation.
Behrouzi A; Bouzari S; Vaziri F; Fateh A; Afrough P; Vijeh Motlagh AD; Siadat SD
Microb Pathog; 2017 Sep; 110():431-438. PubMed ID: 28735080
[TBL] [Abstract][Full Text] [Related]
29. EF-Tu From Non-typeable
Thofte O; Su YC; Brant M; Littorin N; Duell BL; Alvarado V; Jalalvand F; Riesbeck K
Front Immunol; 2018; 9():2910. PubMed ID: 30619274
[TBL] [Abstract][Full Text] [Related]
30. Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin.
Hotomi M; Saito T; Yamanaka N
Vaccine; 1998 Dec; 16(20):1950-6. PubMed ID: 9796049
[TBL] [Abstract][Full Text] [Related]
31. Serum Concentrations of Antibodies against Outer Membrane Protein P6, Protein D, and T- and B-Cell Combined Antigenic Epitopes of Nontypeable Haemophilus influenzae in Children and Adults of Different Ages.
Hua CZ; Hu WL; Shang SQ; Li JP; Hong LQ; Yan J
Clin Vaccine Immunol; 2016 Feb; 23(2):155-61. PubMed ID: 26677200
[TBL] [Abstract][Full Text] [Related]
32. Immune enhancement of pulmonary clearance of nontypable Haemophilus influenzae.
Hansen EJ; Hart DA; McGehee JL; Toews GB
Infect Immun; 1988 Jan; 56(1):182-90. PubMed ID: 3257203
[TBL] [Abstract][Full Text] [Related]
33. Why we need a vaccine for non-typeable Haemophilus influenzae.
Cerquetti M; Giufrè M
Hum Vaccin Immunother; 2016 Sep; 12(9):2357-61. PubMed ID: 27171854
[TBL] [Abstract][Full Text] [Related]
34. Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.
Yu S; Gu XX
Infect Immun; 2007 Jun; 75(6):2974-80. PubMed ID: 17371852
[TBL] [Abstract][Full Text] [Related]
35. Recognition of conserved antigens by Th17 cells provides broad protection against pulmonary
Li W; Zhang X; Yang Y; Yin Q; Wang Y; Li Y; Wang C; Wong SM; Wang Y; Goldfine H; Akerley BJ; Shen H
Proc Natl Acad Sci U S A; 2018 Jul; 115(30):E7149-E7157. PubMed ID: 29987031
[TBL] [Abstract][Full Text] [Related]
36. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media.
Sabirov A; Kodama S; Hirano T; Suzuki M; Mogi G
Infect Immun; 2001 May; 69(5):2964-71. PubMed ID: 11292713
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.
Gu XX; Chen J; Barenkamp SJ; Robbins JB; Tsai CM; Lim DJ; Battey J
Infect Immun; 1998 May; 66(5):1891-7. PubMed ID: 9573066
[TBL] [Abstract][Full Text] [Related]
38. A P5 peptide that is homologous to peptide 10 of OprF from Pseudomonas aeruginosa enhances clearance of nontypeable Haemophilus influenzae from acutely infected rat lung in the absence of detectable peptide-specific antibody.
Webb DC; Cripps AW
Infect Immun; 2000 Jan; 68(1):377-81. PubMed ID: 10603411
[TBL] [Abstract][Full Text] [Related]
39. Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.
Murphy TF
Clin Vaccine Immunol; 2015 May; 22(5):459-66. PubMed ID: 25787137
[TBL] [Abstract][Full Text] [Related]
40. Intranasal immunization with recombinant outer membrane protein P6 induces specific immune responses against nontypeable Haemophilus influenzae.
Hotomi M; Yamanaka N; Shimada J; Suzumoto M; Ikeda Y; Sakai A; Arai J; Green B
Int J Pediatr Otorhinolaryngol; 2002 Sep; 65(2):109-16. PubMed ID: 12176180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
